Novartis Vision Drug Shows

In the “wet” type of macular degeneration, abnormal blood vessels (known as choroidalneovascularization or CNV) grow under the retina and macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from its normally flat position, thus distorting or destroying central vision.

Novartis Vision Drug Shows Positive Results in Phase 3 Trials

By Euan Conley

Novartis AG (NOVN.EB) said on Friday that the results of two phase 3 trials of brolucizumab, a treatment for neovascular age-related macular degeneration, or nAMD, led to “significantly fewer” patients showing signs of disease activity and retinal fluid.

“The absence of fluid for patients in the brolucizumab arm suggests the potential for a long-lasting effect and decreased treatment need,” Novartis said.

 nAMD is a condition that causes rapid deterioration in central vision. Drug therapies for nAMD usually require frequent injections into the eye. The pharmaceuticals company described brolucizumab as the first and only anti-vascular edothelial growth treatment to show visual gains with a majority of patients with less frequent 12-week treatment intervals after the loading phase in randomized clinical trial……
Source: Fox Business